TFF Pharmaceuticals Inc. (TFFP) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results
March 10, 2021 4:00 PM ESTReports positive Phase 1 study results for Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder
Awarded subcontract license by U.S. government agency to formulate biologic countermeasures to be used by the U.S. military
Announces feasibility agreements with Greenlight Biosciences for Covid-19 mRNA Vaccine Reformulation and NeuroRx for Covid-19 therapeutic for critically ill patients
Conference call and live webcast scheduled today, Wednesday, March 10, 2021 at 4:30pm EST
AUSTIN, Texas--(BUSINESS WIRE)-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical... More
